XERIS BIOPHARMA HOLDINGS INC (XERS)

Company Profile

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. The company is headquartered in Chicago, Illinois and currently employs 355 full-time employees. The company went IPO on 2018-06-21. The firm is focused on improving patients’ lives by developing and commercializing products across a range of therapies. The firm has three commercial products: Gvoke, Keveyis and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Its product candidate also includes Ogluo (EU), and Levothyroxine (XP-8121). XP-8121, is an early-stage program designed to address maintenance therapy in patients with congenital or acquired hypothyroidism who require continuous thyroid hormone replacement.

Company Info

XERIS BIOPHARMA HOLDINGS INC

1375 West Fulton Street, Suite 1300

Chicago ILLINOIS 60601

P: 18444455704

CEO: Paul R. Edick

Employees: 355

Website: https://www.xerispharma.com/